Not Tagged
mirati
['$mrtx']
$mrtx asco 2023
phase 2 data: number: 63 patients, late stages profile: pre-treated, median 2 lines of treatments overall response rate (orr): 35% progression-free survival (pfs): 7.4 mo safety: 1.6% grade 4 adverse events, 0 g5 ae 
Self-professed investor in the ABC of tech: Autonomous EV (Tesla, I needed an excuse for A), Biotech and China tech

Display pic: NK Cell in Cells at Work anime